A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

The purpose of this study is to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Chemotherapy-induced nausea and vomiting (CINV) is a serious complication of treatments of hematological malignancies. Although aprepitant has been shown to control CINV in highly emetogenic therapies for solid tumors, the antiemetic effect of aprepitant in hematological chemotherapies is still not clear. In this multi-central perspective randomized controlled study, the investigators are trying to evaluate the efficacy and safety of additional aprepitant to standard antiemetic regimen in Autologous Hematopoietic Stem Cell Transplantation.

Inclusion Criteria:

• Men and women >/= 18 years, <65 years
• Patients with lymphoma receiving autologous hematopoietic stem cell transplantation for the first time
• ECOG 0-2
• TBIL,AST and ALT < 2.5-fold upper normal range
• Female and male subjects of childbearing potential must agree to use a medically accepted method of adequate contraception.
• Signed informed consent

Exclusion Criteria:

• Prior autologous/ allogeneic hematopoietic stem cell transplantation for lymphoma
• Women who are pregnant or breast feeding.
• Serious or uncontroled infection
• Serious complications
• Severe renal or hepatic disease
• Severe mental or nervous system diseases